Mon, Sep 09, 2013 - Page 13 News List

FEATURE: Investors in breast and colorectal cancer drugs sought

BUSINESS MODEL:Revenue will be made by offering manufacturing and research services to other drugmakers to make the recombinant proteins and biosimilar drugs

By Camaron Kao  /  Staff reporter

He estimated the market values for both drugs are about US$6 billion each. To fund its capital spending, and research and development, the company plans to raise another NT$450 million to NT$600 million in the second half of next year. The company is looking for foreign investors to participate in the fund-raising, Liu said.

However, EirGenix is not without possible competitors. Mycenax Biotech Inc (永昕生醫) is building a factory with a capacity of 2,000 liters, while Amaran Biotechnology Inc (潤雅生技) is constructing a factory for the manufacture of Botox, which is widely used in cosmetic surgery. PharmaEssentia Corp (藥華醫藥) has a factory to make 1 million units of drugs a year.

This story has been viewed 1810 times.
TOP top